Predictive value of fibrinogen in identifying inflammatory bowel disease in active stage.

Patients with IBD included were followed up in the First Affiliated Hospital of Wenzhou Medical University during the period which began in September 2011 and ended in September 2019. The IBD diagnosis was based on a combination of clinical features, laboratory results, radiological findings, endoscopic findings, and histopathology. Exclusion criteria were as follows: (a) other immune related diseases, (b) infections, (c) carcinoma, (d) cirrhosis, (e) renal failure, (f) heart failure, (g) respiratory failure, and (h) fibrinogen data lost at admission. According to the criteria above, 788 patients with IBD (245 UC, 543 CD) were included in this retrospective research. Data were extracted from the medical database including epidemiological characteristics such as age, sex, body mass index, and duration of disease; laboratory parameters such as neutrophil, monocyte, lymphocyte, hemoglobin, RDW, platelet, prothrombin time, international normalized ratio, ESR, CRP, and fibrinogen; and endoscopic findings. Duration of disease indicated what moment of the disease the patients were in when recruited, which ranged from 0.5 to 4.0 years in patients with UC and 0.6 to 3.5 years in patients with CD. The CBC parameters were measured including NLR, LMR, and PLR. The Crohn disease activity index (CDAI) and Mayo score assessed disease activity of CD and UC respectively. Mayo score was a comprehensive scoring system which contained defecation situation, endoscopic results, rectal bleeding, and doctor’s overall evaluation [ 21 , 22 ]. Patients with UC can be simply and effectively classified by the Mayo score and the score more than 2 indicated that patients with UC were in active stage. The CDAI criteria included body weight, general health condition, hematocrit, abdominal pain severity, daily blood stool count, and complications [ 23 ]. The CDAI more than 150 indicated that patients with CD were in active stage. Quantitative variables were expressed median [interquartile range (IQR)], compared by Mann–Whitney U test. Categorical variables were expressed absolute numbers (frequencies), compared by Chi-square test or Fisher’ s exact test. Independent association between biomarkers and disease activity in patients with UC or CD was investigated by multivariate logistic regression analyses to calculate odds ratio with a confidence interval of 95%. The Spearman’ s correlation analysis determined the relationship of biomarkers with the IBD activity. The accuracy of biomarkers in discriminating disease states was evaluated by the area under the receiver operating characteristic curve (AUROC). Calibration of fibrinogen was evaluated by Hosmer–Lemeshow goodness of fit test for significance ( P  > 0.05). DeLong test compared AUROCs of various biomarkers [ 24 ]. The sensitivity and specificity were compared at an optimum cut-off value according to the curve. Patients in UC and CD cohorts were respectively divided into two groups by the optimum cut-off values of fibrinogen. All tests were two sided. P  < 0.05 indicated that the difference was statistically significant. STATA (version 14.0; StataCorp, State of Texas, USA) was used for statistics.

A total of 788 patients diagnosed with IBD were included, consisted of 245 (31.1%) with UC and 543 (68.9%) with CD. Table 1 listed characteristics of the subjects we included. Patients in CD cohort was younger than those in UC cohort on the whole. In the UC cohort, the median age was 49 years (37–60 years), and 129 (52.7%) were male, with median disease duration of 1.7 years (0.5–4.0 years). 73 (29.8%) patients were divided into UC remission group while 172 (70.2%) were categorized as UC active group. In the CD cohort, the median age was 27 years (22–33 years), and 396 (72.9%) were male, with median disease duration of 1.8 years (0.6–3.5 years). 257 (47.3%) patients were classified into CD remission group while 286 (52.7%) were categorized as CD active group. Table 1 Characteristics of the inflammatory bowel disease cohort Parameter UC cohort (N = 245) CD cohort (N = 543) Age (years) 49 (37–60) 27 (22–33) Sex: male 129 (52.7) 396 (72.9) BMI (kg/m 2 ) 19.5 (18.4–21.2) 18.9 (17.4–20.9) Smoking: yes 39 (15.9) 84 (15.5) Drinking: yes 22 (9.0) 44 (8.1) Duration of disease (years) 1.7 (0.5–4.0) 1.8 (0.6–3.5) Endoscopic inflammatory localization of disease Proctitis 45 (18.4) – Left-side colitis 107 (43.7) – Extensive colitis 93 (38.0) – Terminal ileitis – 130 (23.9) Colitis – 107 (19.7) Ileocolitis – 306 (56.4) Remission stage 73 (29.8) 257 (47.3) Active stage 172 (70.2) 286 (52.7) Values are expressed as n (%) or median (IQR). UC, ulcerative colitis; CD, Crohn’ s disease; BMI, body mass index Characteristics of the inflammatory bowel disease cohort Values are expressed as n (%) or median (IQR). UC, ulcerative colitis; CD, Crohn’ s disease; BMI, body mass index The fibrinogen, CRP, ESR, PLR, and NLR levels in patients with UC in active stage scored significantly higher than those in remission stage, whereas the LMR levels were significantly lower (all P  < 0.001) as presented in Table 2 . As Table 3 showed, in patients with CD in active stage, the fibrinogen, RDW, CRP, ESR, PLR, and NLR levels were significantly higher while the LMR levels scored significantly lower compared with those in remission stage (all P  < 0.001). Multivariate analysis demonstrated that fibrinogen, body mass index, monocyte, and CRP were independent predictors to identify UC in active stage. In addition, fibrinogen, age, sex, body mass index, duration of disease, neutrophil, lymphocyte, hemoglobin, and CRP were independent predictors to identify CD in active stage. More details about multivariate analysis results of disease activity for patients with IBD were presented in Table 4 . Table 2 Epidemiology and laboratory parameters of ulcerative colitis patients, stratified by disease activity Parameter UC remission (N = 73) UC active (N = 172) P value Age (years) 47 (37–57) 50 (38–61) 0.331 Sex: male 32 (43.8) 97 (56.4) 0.072 BMI (kg/m 2 ) 20.6 (18.8–21.7) 19.3 (18.3–20.8) 0.001 Smoking: yes 10 (13.7) 29 (16.9) 0.536 Drinking: yes 7 (9.6) 15 (8.7) 0.828 Duration of disease (years) 2.0 (0.7–4.3) 1.1 (0.3–3.8) 0.042 Neutrophil (10 9 /L) 3.3 (2.7–4.4) 4.6 (3.4–7.2)  < 0.001 Monocyte (10 9 /L) 0.4 (0.4–0.6) 0.7 (0.5–0.9)  < 0.001 Lymphocyte (10 9 /L) 1.7 (1.5–2.2) 1.8 (1.3–2.2) 0.428 Hb (g/dL) 12.8 (12.0–13.5) 11.9 (10.4–13.2)  < 0.001 RDW (%) 13.2 (12.7–13.9) 13.3 (12.7–14.3) 0.635 Platelet (10 9 /L) 235 (201–270) 281 (214–376)  < 0.001 PT (s) 13.4 (12.9–13.7) 13.7 (13.1–14.6)  < 0.001 INR 1.0 (1.0–1.1) 1.1 (1.0–1.1)  < 0.001 Fibrinogen (g/L) 2.7 (2.3–3.2) 4.0 (3.0–5.0)  < 0.001 CRP (mg/L) 3.0 (1.5–3.2) 12.8 (3.8–32.8)  < 0.001 ESR (mm/h) 6 (2–15) 21 (11–37)  < 0.001 NLR 1.8 (1.3–2.7) 2.8 (1.9–4.2)  < 0.001 PLR 130.0 (100.0–174.1) 166.4 (121.6–222.5)  < 0.001 LMR 4.2 (3.4–5.1) 2.7 (1.8–3.5)  < 0.001 Values are expressed as n (%) or median (IQR). UC ulcerative colitis; BMI body mass index; Hb hemoglobin; RDW red cell distribution width; PT prothrombin time; INR international normalized ratio; CRP C-reactive protein; ESR erythrocyte sedimentation rate; NLR neutrophil to lymphocyte ratio; PLR platelet to lymphocyte ratio; LMR lymphocyte to monocyte ratio Table 3 Epidemiology and laboratory parameters of Crohn’ s disease patients, stratified by disease activity Parameter CD remission (N = 257) CD active (N = 286) P value Age (years) 27 (22–30) 26 (22–36) 0.641 Sex: male 185 (72.0) 211 (73.8) 0.639 BMI (kg/m 2 ) 19.6 (18.3–21.6) 18.2 (16.4–20.2)  < 0.001 Smoking: yes 35 (13.6) 49 (17.1) 0.258 Drinking: yes 14 (5.4) 30 (10.5) 0.032 Duration of disease (years) 2.0 (1.0–3.5) 1.1 (0.3–3.5)  < 0.001 Neutrophil (10 9 /L) 3.5 (2.7–4.4) 5.1 (3.5–7.1)  < 0.001 Monocyte (10 9 /L) 0.5 (0.4–0.6) 0.7 (0.5–0.9)  < 0.001 Lymphocyte (10 9 /L) 1.5 (1.1–1.9) 1.2 (0.9–1.7)  < 0.001 Hb (g/dL) 13.5 (12.2–14.7) 11.5 (10.1–12.6)  < 0.001 RDW (%) 13.4 (12.7–14.9) 14.8 (13.3–16.6)  < 0.001 Platelet (10 9 /L) 246 (206–294) 328 (254–414)  < 0.001 PT (seconds) 13.5 (13.1–14.0) 14.0 (13.3–14.7)  < 0.001 INR 1.1 (1.0–1.1) 1.1 (1.0–1.2)  < 0.001 Fibrinogen (g/L) 3.0 (2.4–3.6) 4.7 (3.9–5.6)  < 0.001 CRP (mg/L) 3.0 (1.6–8.6) 30.0 (15.6–60.4)  < 0.001 ESR (mm/h) 7 (2–14) 31 (17–48)  < 0.001 NLR 2.2 (1.6–3.3) 4.1 (2.8–6.2)  < 0.001 PLR 168.3 (118.8–231.9) 264.8 (192.1–370.0)  < 0.001 LMR 3.0 (2.3–4.2) 1.9 (1.4–2.6)  < 0.001 Values are expressed as n (%) or median (IQR). CD, Crohn’ s disease; BMI body mass index; Hb hemoglobin; RDW red cell distribution width; PT prothrombin time; INR international normalized ratio; CRP C-reactive protein; ESR erythrocyte sedimentation rate; NLR neutrophil to lymphocyte ratio; PLR platelet to lymphocyte ratio; LMR lymphocyte to monocyte ratio Table 4 Multivariate logistic regression analysis results of disease activity for patients with inflammatory bowel disease 95% CI OR Lower Upper P value UC BMI 0.806 0.696 0.935 0.004 Monocyte 8.848 1.662 47.111 0.011 CRP 1.099 1.035 1.168 0.002 Fibrinogen 2.247 1.428 3.537  < 0.001 CD Age 1.059 1.026 1.092  < 0.001 Sex: male 4.975 2.254 10.981  < 0.001 BMI 0.750 0.663 0.847  < 0.001 Duration of disease 0.865 0.780 0.961 0.007 Neutrophil 1.380 1.154 1.651  < 0.001 Lymphocyte 0.593 0.353 0.996 0.048 Hb 0.484 0.392 0.597  < 0.001 CRP 1.112 1.068 1.157  < 0.001 Fibrinogen 2.124 1.433 3.148  < 0.001 ORs and P values were estimated using multivariate logistic regression. Age, sex, and variables were statistically significant in the tests were included in the multivariate analysis. OR odds ratio; CI confidence interval; UC ulcerative colitis; BMI body mass index; CRP C-reactive protein; CD Crohn’s disease; Hb hemoglobin Epidemiology and laboratory parameters of ulcerative colitis patients, stratified by disease activity Values are expressed as n (%) or median (IQR). UC ulcerative colitis; BMI body mass index; Hb hemoglobin; RDW red cell distribution width; PT prothrombin time; INR international normalized ratio; CRP C-reactive protein; ESR erythrocyte sedimentation rate; NLR neutrophil to lymphocyte ratio; PLR platelet to lymphocyte ratio; LMR lymphocyte to monocyte ratio Epidemiology and laboratory parameters of Crohn’ s disease patients, stratified by disease activity Values are expressed as n (%) or median (IQR). CD, Crohn’ s disease; BMI body mass index; Hb hemoglobin; RDW red cell distribution width; PT prothrombin time; INR international normalized ratio; CRP C-reactive protein; ESR erythrocyte sedimentation rate; NLR neutrophil to lymphocyte ratio; PLR platelet to lymphocyte ratio; LMR lymphocyte to monocyte ratio Multivariate logistic regression analysis results of disease activity for patients with inflammatory bowel disease ORs and P values were estimated using multivariate logistic regression. Age, sex, and variables were statistically significant in the tests were included in the multivariate analysis. OR odds ratio; CI confidence interval; UC ulcerative colitis; BMI body mass index; CRP C-reactive protein; CD Crohn’s disease; Hb hemoglobin Table 5 indicated correlations among biomarkers and disease activity of IBD. Fibrinogen, RDW, ESR, CRP, NLR, and PLR had significantly positive correlations with the Mayo score of UC, whereas LMR was negatively related to the Mayo score of UC (all P  < 0.001). Besides, the correlation analysis showed significantly positive correlations of CDAI with the fibrinogen, RDW, ESR, CRP, NLR, and PLR and negative correlations with LMR (all P  < 0.001). Table 5 Spearman correlation coefficients between biomarkers and disease activity of inflammatory bowel disease UC (Mayo score) CD (CDAI) Biomarkers r value P value r value P value RDW 0.147 0.022 0.361  < 0.001 ESR 0.438  < 0.001 0.636  < 0.001 CRP 0.599  < 0.001 0.753  < 0.001 NLR 0.399  < 0.001 0.444  < 0.001 PLR 0.311  < 0.001 0.428  < 0.001 LMR  − 0.499  < 0.001  − 0.452  < 0.001 Fibrinogen 0.529  < 0.001 0.625  < 0.001 P and r values were estimated using Spearman correlation analysis. UC ulcerative colitis; CD Crohn’ s disease; CDAI Crohn’ s disease activity index; RDW red cell distribution width; ESR erythrocyte sedimentation rate; CRP C-reactive protein; NLR neutrophil to lymphocyte ratio; PLR platelet to lymphocyte ratio; LMR lymphocyte to monocyte ratio Spearman correlation coefficients between biomarkers and disease activity of inflammatory bowel disease P and r values were estimated using Spearman correlation analysis. UC ulcerative colitis; CD Crohn’ s disease; CDAI Crohn’ s disease activity index; RDW red cell distribution width; ESR erythrocyte sedimentation rate; CRP C-reactive protein; NLR neutrophil to lymphocyte ratio; PLR platelet to lymphocyte ratio; LMR lymphocyte to monocyte ratio Figures  1 and 2 showed that fibrinogen had higher discriminative capacity for both UC and CD in active stage as compared to RDW, ESR, NLR, PLR, and LMR. CRP performed the best while RDW performed the worst. A fibrinogen cut-off value of 3.22 had a sensitivity of 70% and specificity of 77% for active UC. For active CD, a fibrinogen cut-off value of 3.87 had a sensitivity of 77% and specificity of 81%. More details about the performance of various biomarkers were presented in Tables 6 and 7 . Fibrinogen had good calibration for disease activity of both UC ( P  = 0.512) and CD ( P  = 0.455). Fig. 1 Receiver operating characteristic curves of various biomarkers in identifying active ulcerative colitis. RDW red cell distribution width; ESR erythrocyte sedimentation rate; CRP C-reactive protein; NLR neutrophil to lymphocyte ratio; PLR platelet to lymphocyte ratio; LMR lymphocyte to monocyte ratio Fig. 2 Receiver operating characteristic curves of various biomarkers in identifying active Crohn’s disease. RDW red cell distribution width; ESR erythrocyte sedimentation rate; CRP C-reactive protein; NLR neutrophil to lymphocyte ratio; PLR platelet to lymphocyte ratio; LMR lymphocyte to monocyte ratio Table 6 Diagnostic accuracy of various biomarkers in identifying ulcerative colitis in active stage Biomarkers AUROC 95% CI P value Cut-off Sensitivity Specificity PV +  PV −  LR +  LR −  RDW 0.519 0.443–0.596  < 0.001 13.7 0.40 0.71 0.77 0.34 1.39 0.84 ESR 0.764 0.701–0.828 0.222 16.0 0.67 0.77 0.87 0.50 2.90 0.42 CRP 0.814 0.760–0.868 0.795 3.32 0.79 0.75 0.88 0.60 3.21 0.28 NLR 0.683 0.611–0.756 0.003 2.01 0.67 0.63 0.81 0.45 1.82 0.52 PLR 0.643 0.570–0.716  < 0.001 132 0.70 0.56 0.79 0.44 1.59 0.54 LMR 0.762 0.697–0.826 0.282 3.59 0.77 0.73 0.87 0.58 2.82 0.31 Fibrinogen 0.806 0.751–0.861 Ref 3.22 0.70 0.77 0.88 0.52 3.02 0.39 DeLong test was used to compare the AUROC between fibrinogen and other biomarkers and estimate P values and fibrinogen was the reference. AUROC area under the receiver operating characteristic curve; CI confidence interval; PV  + positive predictive value; PV  − negative predictive value; LR  + positive likelihood ratio; LR  − negative likelihood ratio; RDW red cell distribution width; ESR erythrocyte sedimentation rate; CRP C-reactive protein; NLR neutrophil to lymphocyte ratio; PLR platelet to lymphocyte ratio; LMR lymphocyte to monocyte ratio Table 7 Diagnostic accuracy of various biomarkers in identifying Crohn’ s disease in active stage Biomarkers AUROC 95% CI P value Cut-off Sensitivity Specificity PV +  PV −  LR +  LR −  RDW 0.661 0.615–0.707  < 0.001 14.0 0.65 0.62 0.66 0.61 1.71 0.57 ESR 0.849 0.816–0.882 0.188 21.0 0.70 0.87 0.86 0.72 5.45 0.35 CRP 0.916 0.893–0.938  < 0.001 14.8 0.77 0.89 0.89 0.78 7.32 0.26 NLR 0.758 0.717–0.798  < 0.001 3.32 0.66 0.75 0.75 0.67 2.65 0.45 PLR 0.739 0.698–0.781  < 0.001 247 0.57 0.79 0.75 0.62 2.75 0.55 LMR 0.754 0.714–0.795  < 0.001 2.67 0.79 0.61 0.69 0.73 2.04 0.34 Fibrinogen 0.869 0.839–0.899 Ref 3.87 0.77 0.81 0.82 0.76 4.12 0.28 DeLong test was used to compare the AUROC between fibrinogen and other biomarkers and estimate P values and fibrinogen was the reference. AUROC area under the receiver operating characteristic curve; CI confidence interval; PV  + positive predictive value; PV  − negative predictive value; LR  + positive likelihood ratio; LR  − negative likelihood ratio; RDW red cell distribution width; ESR erythrocyte sedimentation rate; CRP C-reactive protein; NLR neutrophil to lymphocyte ratio; PLR platelet to lymphocyte ratio; LMR lymphocyte to monocyte ratio Receiver operating characteristic curves of various biomarkers in identifying active ulcerative colitis. RDW red cell distribution width; ESR erythrocyte sedimentation rate; CRP C-reactive protein; NLR neutrophil to lymphocyte ratio; PLR platelet to lymphocyte ratio; LMR lymphocyte to monocyte ratio Receiver operating characteristic curves of various biomarkers in identifying active Crohn’s disease. RDW red cell distribution width; ESR erythrocyte sedimentation rate; CRP C-reactive protein; NLR neutrophil to lymphocyte ratio; PLR platelet to lymphocyte ratio; LMR lymphocyte to monocyte ratio Diagnostic accuracy of various biomarkers in identifying ulcerative colitis in active stage DeLong test was used to compare the AUROC between fibrinogen and other biomarkers and estimate P values and fibrinogen was the reference. AUROC area under the receiver operating characteristic curve; CI confidence interval; PV  + positive predictive value; PV  − negative predictive value; LR  + positive likelihood ratio; LR  − negative likelihood ratio; RDW red cell distribution width; ESR erythrocyte sedimentation rate; CRP C-reactive protein; NLR neutrophil to lymphocyte ratio; PLR platelet to lymphocyte ratio; LMR lymphocyte to monocyte ratio Diagnostic accuracy of various biomarkers in identifying Crohn’ s disease in active stage DeLong test was used to compare the AUROC between fibrinogen and other biomarkers and estimate P values and fibrinogen was the reference. AUROC area under the receiver operating characteristic curve; CI confidence interval; PV  + positive predictive value; PV  − negative predictive value; LR  + positive likelihood ratio; LR  − negative likelihood ratio; RDW red cell distribution width; ESR erythrocyte sedimentation rate; CRP C-reactive protein; NLR neutrophil to lymphocyte ratio; PLR platelet to lymphocyte ratio; LMR lymphocyte to monocyte ratio On the basis of the fibrinogen classification for patients with UC (Group A: < 3.22 and Group B: ≥ 3.22), the active UC patients rates among Group A and B were 47.7% (51/107), and 87.7% (121/138) respectively ( P  < 0.001). While, on the basis of the fibrinogen classification for patients with CD (Group C: < 3.87 and Group D: ≥ 3.87), the active CD patients rates among Group C and D were 24.0% (66/275), and 82.1% (220/268) respectively ( P  < 0.001). It is clear that the probability of patients with IBD in active stage significantly increased when fibrinogen was ≥ the optimal cut-off values.

Inflammatory bowel disease (IBD), a chronic recurrent immunologic disease caused by interaction of environmental and genetic factors, become a worldwide health care issue due to its increasingly high incidence and prevalence [ 1 – 3 ]. Crohn’ s disease (CD) and ulcerative colitis (UC), major types of IBD, appear to result from dysregulation of the immune system [ 4 ]. Early detection of disease activity of IBD is conducive to treating the disease timely and preventing the complications effectively so as to improve quality of life and prognosis of patients [ 5 – 7 ]. Endoscopic biopsy remains the golden criterion for assessing and monitoring inflammatory activity of IBD in despite of many efforts to discover new biomarkers [ 8 – 10 ]. However, it has limited use as a result of its invasive nature and the need to collect specimens. Therefore, in order to optimally manage patients with IBD, there is a urgent need for readily obtainable and low-cost markers that enable to evaluate the disease activity of IBD. In recent years, the lymphocyte to monocyte ratio (LMR), platelet to lymphocyte ratio (PLR), and neutrophil to lymphocyte ratio (NLR), which were acquired from the complete blood count (CBC), had been proven to be effective indicators to predict disease activity and severity of IBD [ 11 – 14 ]. Besides, red blood cell distribution width (RDW) had a good ability to evaluate disease activity in CD while RDW performed badly for UC [ 15 ]. Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) were demonstrated to be significant to early diagnose IBD and accurately monitor its disease activity [ 9 , 16 , 17 ]. Inflammation and coagulation were interdependent processes, each activating and propagating the other, which was crucial for the progression of IBD [ 18 , 19 ]. Distinct pro-inflammatory stimuli activated the clotting cascade, which in turn propagated the inflammatory state by activating signaling pathways, or recruiting more inflammatory cells to the inflamed tissue [ 19 ]. Fibrinogen, as factor I in the coagulation process, can also modify multiple aspects of inflammatory cell function by engaging leukocytes through various cellular receptors and mechanisms [ 20 ]. However, we discovered that little was known about the value of fibrinogen in identifying IBD in active stage. Therefore, in this study, we elucidated the association of fibrinogen with IBD activity and externally validated the diagnostic ability of fibrinogen to identify active IBD.

Our study externally validated for the first time fibrinogen’ s diagnostic ability to identify patients with IBD in active stage. It is necessary to timely determine the disease activity of IBD so that we can select optimal treatment and improve the prognosis of patients. Endoscopic biopsy is the golden criterion for assessing and monitoring inflammatory activity of IBD. As for noninvasive biomarker, fecal calprotectin prove to be currently the best biological indicator to discriminate patients with IBD and evaluate disease activity of IBD [ 25 – 28 ]. While, it cannot be widely used in clinical practice due to its high cost, long time requirement, and inconvenience to collect and process samples. Therefore, it is necessary and urgent to search for a simple, accessible and efficient biomarker. Fibrinogen deposits are a near-universal feature of tissue injury including injury driven by immunological derangements [ 20 ]. IBD was an abnormal immune-mediated inflammatory disease of the intestine [ 2 , 4 ]. Thus, we proposed fibrinogen, a new biomarker to identify patients with IBD in active stage. Our research found fibrinogen levels in patients with IBD in active stage significantly increased compared with those in remission stage. The correlation analysis showed significantly positive correlations of fibrinogen with the Mayo score of UC and the CDAI of CD. Through multivariate analysis to adjust for other parameters, our study further proved fibrinogen was an independent factor to distinguish disease activity of UC and CD. Fibrinogen had higher discriminative capacity for both UC (AUROC: 0.806, 0.751–0.861) and CD (AUROC: 0.869, 0.839–0.899) in active stage compared with RDW, ESR, NLR, PLR, and LMR. Besides, we found CRP performed better than fibrinogen in identifying active IBD. Fibrinogen may be a useful adjunct to or used in conjunction with CRP to quickly and timely identify active IBD. Moreover, we respectively divided patients in UC and CD cohorts into two groups by the optimum cut-off values of fibrinogen. And we found the probability of patients with IBD in active stage significantly increased when fibrinogen was ≥ the optimal cut-off values. This biomarker has its own unique advantages. First, fibrinogen values can be easily obtained and objectively assessed with an inexpensive and noninvasive blood test. Second, fibrinogen can be used immediately without tedious calculation process. Third, this biomarker has good prediction accuracy and practicality. A fibrinogen more than 3.22 among patients with UC and 3.87 among patients with CD could be an indicator for patients being in active stage. Finally, the fibrinogen classification has some potentially clinical application value in these aspects such as screening of patients with IBD requiring treatment, evaluation of treatment effect, and prediction of IBD complications, which need further study. However, the study had limitations. First, this research was retrospective and single-center. Besides, some factors were not taken into account such as immunosuppressant and corticosteroids use, which may have influence on the inflammatory marker levels. Finally, part of inflammatory markers were included while others were excluded. We will try to solve these problems in the following research.

Among different biomarkers including fibrinogen, RDW, ESR, CRP, NLR, PLR, and LMR, fibrinogen has a high discriminative capacity for active IBD. Fibrinogen is a convenient and practical biomarker to identify patients with IBD in active stage. Further work is warranted to explore and verify other potentially clinical applications of fibrinogen.